Capturing Structure-Activity Relationships from Chemogenomic Spaces

Modeling off-target effects is one major goal of chemical biology, particularly in its applications to drug discovery. Here, we describe a new approach that allows the extraction of structure-activity relationships from large chemogenomic spaces starting from a single chemical structure. Several public source databases, offering a vast amount of data on structure and activity for a large number of different targets, have been investigated for their usefulness in automated structure-activity relationships (SAR) extraction. SAR tables were constructed by assembling similar structures around each query structure that have an activity record for a particular target. Quantitative series enrichment analysis (QSEA) was applied to these SAR tables to identify trends and to transform these trends into topomer CoMFA models. Overall more than 1700 SAR tables with topomer CoMFA models have been obtained from the ChEMBL, PubChem, and ChemBank databases. These models were able to highlight the structural trends associated with various off-target effects of marketed drugs, including cases where other structural similarity metrics would not have detected an off-target effect. These results indicate the usefulness of the QSEA approach, particularly whenever applicable with public databases, in providing a new means, beyond a simple similarity between ligand structures, to capture SAR trends and thereby contribute to success in drug discovery.

[1]  Carlos A. Montanari,et al.  Novel Application of 2D and 3D-Similarity Searches To Identify Substrates among Cytochrome P450 2C9, 2D6, and 3A4 , 2010, J. Chem. Inf. Model..

[2]  Yanli Wang,et al.  PubChem: Integrated Platform of Small Molecules and Biological Activities , 2008 .

[3]  Michael G. Lerner,et al.  Binding MOAD (Mother Of All Databases) , 2005, Proteins.

[4]  Andreas Bender,et al.  Databases: Compound bioactivities go public , 2010 .

[5]  Bernd Wendt,et al.  Quantitative Series Enrichment Analysis (QSEA): a novel procedure for 3D-QSAR analysis , 2008, J. Comput. Aided Mol. Des..

[6]  Mohane Selvaraj Coumar,et al.  Aurora kinase inhibitors in preclinical and clinical testing , 2009, Expert opinion on investigational drugs.

[7]  R. Cramer,et al.  Dbtop: topomer similarity searching of conventional structure databases. , 2002, Journal of molecular graphics & modelling.

[8]  A. Bender,et al.  In silico target fishing: Predicting biological targets from chemical structure , 2006 .

[9]  Ajay N. Jain,et al.  Molecular Shape and Medicinal Chemistry: A Perspective , 2010, Journal of medicinal chemistry.

[10]  H. Matter,et al.  Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and three-dimensional molecular descriptors. , 1997, Journal of medicinal chemistry.

[11]  P. Bork,et al.  Large‐scale prediction of drug–target relationships , 2008, FEBS letters.

[12]  Robert P. Sheridan,et al.  Similarity to Molecules in the Training Set Is a Good Discriminator for Prediction Accuracy in QSAR , 2004, J. Chem. Inf. Model..

[13]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[14]  Jérôme Hert,et al.  Comparison of Fingerprint-Based Methods for Virtual Screening Using Multiple Bioactive Reference Structures , 2004, J. Chem. Inf. Model..

[15]  Jürgen Bajorath,et al.  Mini-fingerprints Detect Similar Activity of Receptor Ligands Previously Recognized Only by Three-Dimensional Pharmacophore-Based Methods , 2001, J. Chem. Inf. Comput. Sci..

[16]  C. Hart,et al.  Finding the target after screening the phenotype. , 2005, Drug discovery today.

[17]  Robert J. Jilek,et al.  Topomers: A Validated Protocol for Their Self-Consistent Generation , 2004, J. Chem. Inf. Model..

[18]  Thierry Kogej,et al.  Multifingerprint Based Similarity Searches for Targeted Class Compound Selection , 2006, J. Chem. Inf. Model..

[19]  Alexander Böcker,et al.  Toward an Improved Clustering of Large Data Sets Using Maximum Common Substructures and Topological Fingerprints , 2008, J. Chem. Inf. Model..

[20]  Z. Deng,et al.  Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.

[21]  Tudor I. Oprea,et al.  An automated PLS search for biologically relevant QSAR descriptors , 2004, J. Comput. Aided Mol. Des..

[22]  Martin Serrano,et al.  Nucleic Acids Research Advance Access published October 18, 2007 ChemBank: a small-molecule screening and , 2007 .

[23]  Xiang-Qun Xie,et al.  Data Mining a Small Molecule Drug Screening Representative Subset from NIH PubChem , 2008, J. Chem. Inf. Model..

[24]  Andrew R. Leach,et al.  SAR Knowledge Bases in Drug Discovery , 2008 .

[25]  G. Terstappen,et al.  Target deconvolution strategies in drug discovery , 2007, Nature Reviews Drug Discovery.

[26]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[27]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.

[28]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[29]  Jordi Mestres,et al.  Anticipating drug side effects by comparative pharmacology , 2010, Expert opinion on drug metabolism & toxicology.

[30]  R. Cramer,et al.  Topomer CoMFA: a design methodology for rapid lead optimization. , 2003, Journal of medicinal chemistry.

[31]  Robert D Clark,et al.  Neighborhood behavior: a useful concept for validation of "molecular diversity" descriptors. , 1996, Journal of medicinal chemistry.

[32]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[33]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[34]  Tudor I. Oprea,et al.  Systems chemical biology. , 2007 .

[35]  Ajay N. Jain,et al.  Robust ligand-based modeling of the biological targets of known drugs. , 2006, Journal of medicinal chemistry.

[36]  Marc W. Kirschner,et al.  Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling , 2009, Nature.

[37]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[38]  T. Nishikawa,et al.  A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[39]  Randall T Peterson,et al.  Chemical biology and the limits of reductionism. , 2008, Nature chemical biology.

[40]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[41]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.